Subanalysis of the Impact of OLmesartan on theprogression of coronary atherosclerosis: evaluation by IntraVascular UltraSound (OLIVUS) trial

Subanalysis of the Impact of OLmesartan on theprogression of coronary atherosclerosis: evaluation by IntraVascular UltraSound (OLIVUS) trial - the OLIVUS-Biomarker study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008309

Enrollment

200

Registered

2012-06-30

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with stable angina pectoris and hypertension scheduled for PCI

Interventions

olmesartan treatment after PCI medications except for olmesartan after PCI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with clinically stable angina pectoris and hypertension scheduled for PCI

Exclusion criteria

Exclusion criteria: Patinets have complicated lesions (such as excessive tortuosity or calcified lesions, or lesions that could not be cross-sectioned using IVUS), chronic renal failure (serum creatinine >1.5), recent myocardial infarction (within 4 weeks), or poor ejection fraction (<25%); or if they were taking an angiotensin-converting enzyme (ACE) inhibitor or ARB.

Design outcomes

Primary

Measure	Time frame
Chanegin serum biomarkers and the relationship between any biomarker changes and the favorable effect of olmesartan on atheroma progression	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026